VistaGen Therapeutics
VTGN
52 hedge funds and large institutions have $127M invested in VistaGen Therapeutics in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 4 closing their positions.
5,238% more capital invested
Capital invested by funds: $2.39M → $127M (+$125M)
600% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 4
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
86% more funds holding
Funds holding: 28 → 52 (+24)
1.48% more ownership
Funds ownership: 0.15% → 1.63% (+1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$7.96M |
| 2 |
VA
VR Adviser
New York
|
+$7.96M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$6.38M |
| 4 |
O
OrbiMed
New York
|
+$6.38M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$5.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
-$92K |
| 2 |
Goldman Sachs
New York
|
-$48.6K |
| 3 |
LPL Financial
San Diego,
California
|
-$21.3K |
| 4 |
RC
RBF Capital
San Francisco,
California
|
-$17K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
52
HighTower Advisors
Chicago,
Illinois
| – | -$92K | -4,411 | Closed |
|
|
RC
53
RBF Capital
San Francisco,
California
| – | -$17K | -833 | Closed |
|
|
TRCT
54
Tower Research Capital (TRC)
New York
| – | -$13K | -631 | Closed |
|
55
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$9K | -440 | Closed |
|
VTGN Hedge Fund Activity: Q4 2020 in Review
52 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2020, worth a combined $127M — up 5,238% from $2.39M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new VTGN positions and 4 closed out — a net gain of 24 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $7.96M. The largest seller was HighTower Advisors, exiting entirely with an estimated $92K sold.
- 52 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2020, up from 28 in Q3 2020.
- Funds reported $127M of VistaGen Therapeutics stock for Q4 2020, up 5,238% quarter-over-quarter.
- 28 funds opened new VistaGen Therapeutics positions in Q4 2020 and 4 closed out, a net change of +24 holders.
- The largest VistaGen Therapeutics buyer in Q4 2020 was NEA Management Company, an estimated $7.96M added.
- The largest VistaGen Therapeutics seller in Q4 2020 was HighTower Advisors, an estimated $92K sold.
Based on aggregated 13F filings for Q4 2020.